Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$154.2M
27M shares
52-week range
$5.34 – $9.13
12% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
www.inogen.comNo one on the platform currently holds INGN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 478,800 | $3.0M |
No one on the platform has traded INGN yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 0.01 EPS for $INGN Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/ingn?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-6-inogen-inc-stock/ $INGN Inogen Earnings Transcript
View on StockTwits ↗$INGN thanks to the genius pumping this on reddit made it sound really good, down 10%
View on StockTwits ↗$INGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.14 up 6.67% YoY • Reported revenue of $95.08M up 3.04% YoY • Inogen now expects full year 2026 reported revenue in the range of $355 million to $361 million and adjusted EBITDA of approximately $4.0 million, representing a 48.1% increase from 2025.
View on StockTwits ↗$INGN Smartbird Nominates Tech Industry Veterans Elizabeth Mora and Dan Kasun for Election to Its Board of Directors https://marketwirenews.com/stock/ingn/news/smartbird-nominates-tech-industry-veterans-elizabeth-6010493384085063.html?utm_source=stocktwits
View on StockTwits ↗$INGN Never turns a profit, decreasing demand, and increasing SG&A spending. Prove me wrong, looking to invest but don’t see the vision.
View on StockTwits ↗$INGN has announced the appointment of Andy Reding to the newly created role of chief operating officer (COO), effective Monday, July 6, 2026. https://biotuesdays.com/2026/07/02/inogen-appoints-andy-reding-as-coo/
View on StockTwits ↗$INGN Share Price: $6.05 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 59% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$INGN at an EV of $63M I continue to believe there is major value here
View on StockTwits ↗$INGN Q1 '26 Earnings Results & Recap Inogen expects Q2 2026 revenue of $94M to $97M and reiterates full-year 2026 revenue guidance of $366M to $373M, reflecting approximately 6.0% growth.
View on StockTwits ↗$INGN so frustrating, it actually has a strong day, then just casually drops .50 cents after hours
View on StockTwits ↗$INGN Keep in mind, It is still undervalued than book price.
View on StockTwits ↗$INGN's Q4 surprise: Narrower loss, but shares slip! 🤔 💡 Adjusted loss per share of 15 cents beat estimates, yet revenue missed slightly & shares dropped nearly 5% in after-market trading. Strong international sales couldn't offset weaker U.S. performance. Complete risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2875401/inogen-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875401-body-35194&ADID=SYND_STOCKTWITS_TWEET_2_2875401_BODY_35194
View on StockTwits ↗$INGN bests expectations and cashed up with 7M shares float. No debt.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $369M | +4.9% | $-0.78 | $-0.79–$-0.77 | — | 1 |
| 2027 | $397M | +7.5% | $-0.47 | $-0.47–$-0.46 | — | 1 |
| 2028 | $417M | +5.0% | $-0.33 | $-0.51–$-0.15 | — | 2 |
| 2029 | $455M | +9.2% | $0.05 | $0.05–$0.05 | 116.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.15 | $-0.14 | +8.7% |
| 2026-05-07 | $-0.24 | $-0.30 | -25.0% |
| 2026-02-24 | $-0.36 | $-0.26 | +27.8% |
| 2025-11-05 | $-0.22 | $-0.20 | +9.1% |
| 2025-08-07 | $-0.22 | $-0.15 | +31.8% |
| 2025-05-07 | $-0.52 | $-0.25 | +51.9% |
| 2025-02-25 | $-0.56 | $-0.41 | +26.8% |
| 2024-11-07 | $-0.49 |
| $-0.25 |
| +49.0% |
| $105M |
| — |
| NNOXNano-X Imaging Ltd. | $0.98 | -3.43% | $69M | — |
| OMOutset Medical, Inc. | $4.25 | -5.56% | $79M | — |
Source: Financial Modeling Prep · peers by sector/industry